Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma is a phase 2/3 interventional study registered as NCT06697301, led by Eikon Therapeutics with Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Randomised, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006). Planned enrolment is 740 participants (estimated). The study started in 2025-05-22 and primary completion is expected in 2035-12. No results have been posted on ClinicalTrials.gov.